Importantly, some of their shared features are relevant to the drugs prescribed for these diseases: the monoclonal antibodies adalimumab and infliximab are antagonists of TNF (Park and Jeen 2015), whose corresponding gene variation in a number of diseases including CD, UC and psoriasis. This evidence concerns the gene TNF and psoriasis.